These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Kallini JR; Gabr A; Salem R; Lewandowski RJ Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186 [TBL] [Abstract][Full Text] [Related]
4. Radioembolization for the treatment of hepatocellular carcinoma. Kim HC Clin Mol Hepatol; 2017 Jun; 23(2):109-114. PubMed ID: 28494530 [TBL] [Abstract][Full Text] [Related]
5. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. Cappelli A; Pettinato C; Golfieri R J Hepatocell Carcinoma; 2014; 1():163-82. PubMed ID: 27508185 [TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study. Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511 [TBL] [Abstract][Full Text] [Related]
7. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma. Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison. Agirrezabal I; Bouattour M; Pinato DJ; D'Alessio A; Brennan VK; Carion PL; Shergill S; Amoury N; Vilgrain V Eur J Cancer; 2024 Jan; 196():113427. PubMed ID: 37988840 [TBL] [Abstract][Full Text] [Related]
9. Radioembolization for hepatocellular carcinoma: what clinicians need to know. Choi JW; Kim HC J Liver Cancer; 2022 Mar; 22(1):4-13. PubMed ID: 37383534 [TBL] [Abstract][Full Text] [Related]
10. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? El Fouly A; Ertle J; El Dorry A; Shaker MK; Dechêne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497 [TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. Kim DY; Han KH Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821 [TBL] [Abstract][Full Text] [Related]
12. Resin Versus Glass Microspheres for Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436 [TBL] [Abstract][Full Text] [Related]
13. Quantification of Blood Pressure Changes in the Vascular Compartment When Using an Anti-Reflux Catheter during Chemoembolization versus Radioembolization: A Retrospective Case Series. Rose SC; Narsinh KH; Newton IG J Vasc Interv Radiol; 2017 Jan; 28(1):103-110. PubMed ID: 27840042 [TBL] [Abstract][Full Text] [Related]
14. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. Casadei Gardini A; Tamburini E; Iñarrairaegui M; Frassineti GL; Sangro B Onco Targets Ther; 2018; 11():7315-7321. PubMed ID: 30498358 [TBL] [Abstract][Full Text] [Related]
15. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. Wang EA; Stein JP; Bellavia RJ; Broadwell SR Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319 [TBL] [Abstract][Full Text] [Related]